HGF/c-Met Axis: The Advanced Development in Digestive System Cancer

作者：Zhiwei Shao, Haoqi Pan, Sheng Tu, Jingying Zhang, Sheng Yan, Anwen Shao · 发表于：Frontiers in Cell and Developmental Biology · 年份：2020 · DOI：10.3389/fcell.2020.00801 · 被引用次数：24 · 研究领域：Liver physiology and pathology、Pancreatic and Hepatic Oncology Research、Growth Hormone and Insulin-like Growth Factors

Numerous studies have indicated that abnormal activation of the HGF/c-Met signaling pathway can lead to cell proliferation, invasiveness, and metastasis of cancers of the digestive system. Moreover, overexpression of c-Met has been implicated in poor prognosis of patients with these forms of cancer, suggesting the possibility for HGF/c-Met axis as a potential therapeutic target. Despite the large number of clinical and preclinical trials worldwide, no significant positive success in the use of anti-HGF/c-Met treatments on cancers of the digestive system has been achieved. In this review, we summarize advanced development of clinical research on HGF/c-Met antibody and small-molecule c-Met inhibitors of cancers of the digestive system and provide a possible direction for future research.